Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Patent metadata

Field	Value
Publication number	US-2025244311-A1
Application number	US-202418920525-A
Country	US
Kind code	A1
Filing date	Oct 18, 2024
Priority date	May 13, 2016
Publication date	Jul 31, 2025
Grant date	—

Abstract

The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

First claim

1 .- 19 . (canceled)

20 . A method for making a vaccine comprising one or more proteins or fragments thereof expressed by diseased the method comprising:
determining one or more of the following:
(a) an existing antibody response to the one or more proteins or fragments thereof,
(b) whether the one or more proteins or fragments thereof binds to F actin, and
(c) whether the one or more proteins or fragments thereof binds to RNA,

wherein one or more of (a) an existing antibody response to the one or more proteins or fragments thereof, (b) binding of the one or more proteins or fragments thereof to F actin, and (c) binding of the one or more proteins or fragments thereof to RNA, indicates that the one or more proteins or fragments thereof or a nucleic acid encoding said one or more proteins or fragments is useful for immunotherapy; and
manufacturing a vaccine for treating a subject with the diseased cells, or having a vaccine be manufactured, wherein the vaccine comprises one or more proteins or fragments thereof or a nucleic acid encoding said one or more proteins or fragments which are indicated as being useful for immunotherapy.

21 .- 23 . (canceled)

24 . The method of claim 20 , wherein the one or more proteins or fragments thereof comprises a disease-specific amino acid modification.

25 . The method of claim 24 , wherein the amino acid modification is due to a disease-specific somatic mutation.

26 . The method of any one of claims 20, 24, and 25 , wherein the diseased cells are cancer cells.

27 . The method of any one of claims 20, 24, and 25 , wherein the one or more proteins or fragments thereof comprises a neo-antigen expressed by the diseased cells or neo-epitope thereof.

28 .- 32 . (canceled)

33 . The method of claim 20 wherein at least two proteins are determined that have one or more of the following properties:
(a) an existing antibody response to the protein or a fragment thereof,
(b) whether the protein or a fragment thereof binds to F actin, and
(c) whether the protein or a fragment thereof binds to RNA, and

wherein the at least two proteins have disease-specific amino acid modifications.

34 .- 42 . (canceled)

43 . A method for making a vaccine that upon administration to a subject with diseased cells induces an immune response against the diseased cells, the method comprising:
determining one or more of the following:
(a) an existing antibody response to a protein or a fragment thereof expressed by the diseased cells,
(b) whether the protein or the fragment thereof binds to F actin, and
(c) whether the protein or the fragment thereof binds to RNA,

wherein one or more of (a) an existing antibody response to the protein or fragment thereof, (b) binding of the protein or fragment thereof to F actin, and (c) binding of the protein or fragment thereof to RNA, indicates that the protein or fragment thereof or a nucleic acid encoding said protein or fragment is useful for immunotherapy; and
making a vaccine, or having a vaccine made, for administration to a subject with the diseased cells, wherein the vaccine comprises the protein or fragment thereof or a nucleic acid encoding said protein or fragment which are indicated as being useful for immunotherapy.

44 . The method of claim 43 , further comprising formulating the vaccine with a pharmaceutically acceptable carrier.

45 . A method of treating a subject, the method comprising administering to the subject the vaccine made by the method of claim 20 .

46 . The method of claim 45 , wherein the vaccine induces an immune response against diseased cells in the subject.

47 . A method of treating a subject, the method comprising administering to the subject the vaccine made by the method of claim 20 , in combination with a second therapy.

48 . The method of claim 47 , wherein the second therapy comprises one or more of surgical resection, radiation, and chemotherapy.

Assignees

• BioNTech SE
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gg

Inventors

• Vormehr Mathias
• Sahin Ugur
• Schrörs Barbara
• Löwer Martin
• Boegel Sebastian

Classifications

• A61P35/04

  specific for metastasis · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/4712

  Muscle proteins, e.g. myosin, actin, protein · CPC title

• G01N33/6887

  from muscle, cartilage or connective tissue · CPC title

• G01N33/6878 Primary

  in epitope analysis · CPC title